Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 4Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Peripheral Nervous System Diseases 1Colorectal Neoplasms 1Cognitive Dysfunction 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Cyclophosphamide 219Drug Therapy 218Paclitaxel 205apatinib 201Bevacizumab 195camrelizumab 190Fluorouracil 187sintilimab 133Blood Specimen Collection 125Irinotecan 124Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 110Pemetrexed 108anlotinib 105S 1 (combination) 105Surveys and Questionnaires 101Leucovorin 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × Silymarin × Clear all
NCT05631041 2023-12-22

Effect of Silymarin in Metastatic Colorectal Cancer Patients

Tanta University

Phase 3 Unknown
64 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown
56 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡